#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=1. Introduction
1-1	0-2	1.	_	_	_	_
1-2	3-15	Introduction	abstract	new	_	_

#Text=Bone disorders , especially osteoporosis , are becoming increasingly prevalent as the aging population grows , and bone fractures also occur frequently .
2-1	16-20	Bone	person|abstract[3]	new|new[3]	coref	5-1
2-2	21-30	disorders	abstract[3]	new[3]	_	_
2-3	31-32	,	_	_	_	_
2-4	33-43	especially	object[4]	new[4]	_	_
2-5	44-56	osteoporosis	object[4]	new[4]	_	_
2-6	57-58	,	_	_	_	_
2-7	59-62	are	_	_	_	_
2-8	63-71	becoming	_	_	_	_
2-9	72-84	increasingly	_	_	_	_
2-10	85-94	prevalent	_	_	_	_
2-11	95-97	as	_	_	_	_
2-12	98-101	the	abstract[5]	new[5]	_	_
2-13	102-107	aging	abstract[5]	new[5]	_	_
2-14	108-118	population	abstract[5]	new[5]	_	_
2-15	119-124	grows	_	_	_	_
2-16	125-126	,	_	_	_	_
2-17	127-130	and	_	_	_	_
2-18	131-135	bone	object|object[7]	new|new[7]	coref|coref	4-4|13-32[81_7]
2-19	136-145	fractures	object[7]	new[7]	_	_
2-20	146-150	also	_	_	_	_
2-21	151-156	occur	_	_	_	_
2-22	157-167	frequently	_	_	_	_
2-23	168-169	.	_	_	_	_

#Text=Osteoporosis contributes significantly to global healthcare costs , and the treatment of osteoporosis remains a great challenge .
3-1	170-182	Osteoporosis	abstract	new	coref	3-13
3-2	183-194	contributes	_	_	_	_
3-3	195-208	significantly	_	_	_	_
3-4	209-211	to	_	_	_	_
3-5	212-218	global	abstract[10]	new[10]	_	_
3-6	219-229	healthcare	organization|abstract[10]	new|new[10]	_	_
3-7	230-235	costs	abstract[10]	new[10]	_	_
3-8	236-237	,	_	_	_	_
3-9	238-241	and	_	_	_	_
3-10	242-245	the	event[11]	new[11]	_	_
3-11	246-255	treatment	event[11]	new[11]	_	_
3-12	256-258	of	event[11]	new[11]	_	_
3-13	259-271	osteoporosis	event[11]|object	new[11]|giv	coref	4-17
3-14	272-279	remains	_	_	_	_
3-15	280-281	a	abstract[13]	new[13]	_	_
3-16	282-287	great	abstract[13]	new[13]	_	_
3-17	288-297	challenge	abstract[13]	new[13]	_	_
3-18	298-299	.	_	_	_	_

#Text=Thus , new bone anabolic drugs need to be developed for the prevention and treatment of osteoporosis .
4-1	300-304	Thus	_	_	_	_
4-2	305-306	,	_	_	_	_
4-3	307-310	new	substance[16]	new[16]	_	_
4-4	311-315	bone	object|substance[16]	giv|new[16]	coref	5-22
4-5	316-324	anabolic	person|substance[16]	new|new[16]	_	_
4-6	325-330	drugs	substance[16]	new[16]	_	_
4-7	331-335	need	_	_	_	_
4-8	336-338	to	_	_	_	_
4-9	339-341	be	_	_	_	_
4-10	342-351	developed	_	_	_	_
4-11	352-355	for	_	_	_	_
4-12	356-359	the	abstract[17]	new[17]	_	_
4-13	360-370	prevention	abstract[17]	new[17]	_	_
4-14	371-374	and	_	_	_	_
4-15	375-384	treatment	event[18]	new[18]	_	_
4-16	385-387	of	event[18]	new[18]	_	_
4-17	388-400	osteoporosis	event[18]|object	new[18]|giv	coref	10-20
4-18	401-402	.	_	_	_	_

#Text=Bone morphogenetic protein 2 ( BMP2 ) is one of the most important growth factors that induce osteoblast differentiation and stimulate bone or cartilage formation .
5-1	403-407	Bone	person|abstract[21]	giv|new[21]	_	_
5-2	408-421	morphogenetic	abstract[21]	new[21]	_	_
5-3	422-429	protein	abstract[21]	new[21]	_	_
5-4	430-431	2	abstract[21]	new[21]	_	_
5-5	432-433	(	_	_	_	_
5-6	434-438	BMP2	abstract	new	coref	6-1
5-7	439-440	)	_	_	_	_
5-8	441-443	is	_	_	_	_
5-9	444-447	one	abstract[23]	new[23]	_	_
5-10	448-450	of	abstract[23]	new[23]	_	_
5-11	451-454	the	abstract[23]|abstract[25]	new[23]|new[25]	_	_
5-12	455-459	most	abstract[23]|abstract[25]	new[23]|new[25]	_	_
5-13	460-469	important	abstract[23]|abstract[25]	new[23]|new[25]	_	_
5-14	470-476	growth	abstract[23]|abstract|abstract[25]	new[23]|new|new[25]	_	_
5-15	477-484	factors	abstract[23]|abstract[25]	new[23]|new[25]	_	_
5-16	485-489	that	_	_	_	_
5-17	490-496	induce	_	_	_	_
5-18	497-507	osteoblast	event|event[27]	new|new[27]	coref|coref	9-12|9-11[52_27]
5-19	508-523	differentiation	event[27]	new[27]	_	_
5-20	524-527	and	_	_	_	_
5-21	528-537	stimulate	_	_	_	_
5-22	538-542	bone	object	giv	coref	6-11
5-23	543-545	or	_	_	_	_
5-24	546-555	cartilage	object|event[30]	new|new[30]	coref	6-11[34_30]
5-25	556-565	formation	event[30]	new[30]	_	_
5-26	566-567	.	_	_	_	_

#Text=BMP2 has been widely used in the clinic to promote bone formation .
6-1	568-572	BMP2	substance	giv	coref	7-7
6-2	573-576	has	_	_	_	_
6-3	577-581	been	_	_	_	_
6-4	582-588	widely	_	_	_	_
6-5	589-593	used	_	_	_	_
6-6	594-596	in	_	_	_	_
6-7	597-600	the	abstract[32]	new[32]	_	_
6-8	601-607	clinic	abstract[32]	new[32]	_	_
6-9	608-610	to	_	_	_	_
6-10	611-618	promote	_	_	_	_
6-11	619-623	bone	object|event[34]	giv|giv[34]	coref|coref	9-26|19-27[136_34]
6-12	624-633	formation	event[34]	giv[34]	_	_
6-13	634-635	.	_	_	_	_

#Text=However , the therapeutic dose of BMP2 is very expensive , and there are some life-threatening side effects that can occur with larger doses .
7-1	636-643	However	_	_	_	_
7-2	644-645	,	_	_	_	_
7-3	646-649	the	quantity[35]	new[35]	_	_
7-4	650-661	therapeutic	quantity[35]	new[35]	_	_
7-5	662-666	dose	quantity[35]	new[35]	_	_
7-6	667-669	of	quantity[35]	new[35]	_	_
7-7	670-674	BMP2	quantity[35]|abstract	new[35]|giv	coref	8-16[45_0]
7-8	675-677	is	_	_	_	_
7-9	678-682	very	_	_	_	_
7-10	683-692	expensive	_	_	_	_
7-11	693-694	,	_	_	_	_
7-12	695-698	and	_	_	_	_
7-13	699-704	there	_	_	_	_
7-14	705-708	are	_	_	_	_
7-15	709-713	some	abstract[38]	new[38]	coref	8-20[46_38]
7-16	714-730	life-threatening	abstract[38]	new[38]	_	_
7-17	731-735	side	abstract|abstract[38]	new|new[38]	coref	9-20
7-18	736-743	effects	abstract[38]	new[38]	_	_
7-19	744-748	that	_	_	_	_
7-20	749-752	can	_	_	_	_
7-21	753-758	occur	_	_	_	_
7-22	759-763	with	_	_	_	_
7-23	764-770	larger	abstract[39]	new[39]	_	_
7-24	771-776	doses	abstract[39]	new[39]	_	_
7-25	777-778	.	_	_	_	_

#Text=Hence , it is necessary to find additional agents or methods for the improvement of BMP2 itself to intensify the osteogenic effects of BMP2 .
8-1	779-784	Hence	_	_	_	_
8-2	785-786	,	_	_	_	_
8-3	787-789	it	abstract	new	cata	8-3[0_41]
8-4	790-792	is	_	_	_	_
8-5	793-802	necessary	_	_	_	_
8-6	803-805	to	abstract[41]	new[41]	_	_
8-7	806-810	find	abstract[41]	new[41]	_	_
8-8	811-821	additional	abstract[41]|person[42]	new[41]|new[42]	_	_
8-9	822-828	agents	abstract[41]|person[42]	new[41]|new[42]	_	_
8-10	829-831	or	abstract[41]	new[41]	_	_
8-11	832-839	methods	abstract[41]|abstract[43]	new[41]|new[43]	_	_
8-12	840-843	for	abstract[41]|abstract[43]	new[41]|new[43]	_	_
8-13	844-847	the	abstract[41]|abstract[43]|abstract[44]	new[41]|new[43]|new[44]	_	_
8-14	848-859	improvement	abstract[41]|abstract[43]|abstract[44]	new[41]|new[43]|new[44]	_	_
8-15	860-862	of	abstract[41]|abstract[43]|abstract[44]	new[41]|new[43]|new[44]	_	_
8-16	863-867	BMP2	abstract[41]|abstract[43]|abstract[44]|abstract[45]	new[41]|new[43]|new[44]|giv[45]	coref	8-24[0_45]
8-17	868-874	itself	abstract[41]|abstract[43]|abstract[44]|abstract[45]	new[41]|new[43]|new[44]|giv[45]	_	_
8-18	875-877	to	_	_	_	_
8-19	878-887	intensify	_	_	_	_
8-20	888-891	the	abstract[46]	giv[46]	coref	9-19[56_46]
8-21	892-902	osteogenic	abstract[46]	giv[46]	_	_
8-22	903-910	effects	abstract[46]	giv[46]	_	_
8-23	911-913	of	abstract[46]	giv[46]	_	_
8-24	914-918	BMP2	abstract[46]|substance	giv[46]|giv	coref	9-4
8-25	919-920	.	_	_	_	_

#Text=The combination of BMP2 and these small molecules can promote BMP2-mediated osteoblast differentiation and reduces the risk of its side effects in the treatment of bone diseases .
9-1	921-924	The	abstract[48]	new[48]	_	_
9-2	925-936	combination	abstract[48]	new[48]	_	_
9-3	937-939	of	abstract[48]	new[48]	_	_
9-4	940-944	BMP2	abstract[48]|substance	new[48]|giv	ana	9-19
9-5	945-948	and	abstract[48]	new[48]	_	_
9-6	949-954	these	abstract[48]|substance[50]	new[48]|new[50]	coref	10-6[61_50]
9-7	955-960	small	abstract[48]|substance[50]	new[48]|new[50]	_	_
9-8	961-970	molecules	abstract[48]|substance[50]	new[48]|new[50]	_	_
9-9	971-974	can	_	_	_	_
9-10	975-982	promote	_	_	_	_
9-11	983-996	BMP2-mediated	event[52]	giv[52]	coref	15-14[101_52]
9-12	997-1007	osteoblast	event|event[52]	giv|giv[52]	coref	22-13
9-13	1008-1023	differentiation	event[52]	giv[52]	_	_
9-14	1024-1027	and	_	_	_	_
9-15	1028-1035	reduces	_	_	_	_
9-16	1036-1039	the	abstract[53]	new[53]	_	_
9-17	1040-1044	risk	abstract[53]	new[53]	_	_
9-18	1045-1047	of	abstract[53]	new[53]	_	_
9-19	1048-1051	its	abstract[53]|substance|abstract[56]	new[53]|giv|giv[56]	coref|coref	10-11|14-21[88_56]
9-20	1052-1056	side	abstract[53]|abstract|abstract[56]	new[53]|giv|giv[56]	coref	25-8
9-21	1057-1064	effects	abstract[53]|abstract[56]	new[53]|giv[56]	_	_
9-22	1065-1067	in	abstract[53]|abstract[56]	new[53]|giv[56]	_	_
9-23	1068-1071	the	abstract[53]|abstract[56]|event[57]	new[53]|giv[56]|new[57]	_	_
9-24	1072-1081	treatment	abstract[53]|abstract[56]|event[57]	new[53]|giv[56]|new[57]	_	_
9-25	1082-1084	of	abstract[53]|abstract[56]|event[57]	new[53]|giv[56]|new[57]	_	_
9-26	1085-1089	bone	abstract[53]|abstract[56]|event[57]|object|abstract[59]	new[53]|giv[56]|new[57]|giv|new[59]	coref|coref	13-32|25-16[174_59]
9-27	1090-1098	diseases	abstract[53]|abstract[56]|event[57]|abstract[59]	new[53]|giv[56]|new[57]|new[59]	_	_
9-28	1099-1100	.	_	_	_	_

#Text=From a clinical perspective , these small molecules that regulate BMP2 activity provide powerful tools for the treatment of osteoporosis and fracture repair .
10-1	1101-1105	From	_	_	_	_
10-2	1106-1107	a	abstract[60]	new[60]	_	_
10-3	1108-1116	clinical	abstract[60]	new[60]	_	_
10-4	1117-1128	perspective	abstract[60]	new[60]	_	_
10-5	1129-1130	,	_	_	_	_
10-6	1131-1136	these	substance[61]	giv[61]	_	_
10-7	1137-1142	small	substance[61]	giv[61]	_	_
10-8	1143-1152	molecules	substance[61]	giv[61]	_	_
10-9	1153-1157	that	_	_	_	_
10-10	1158-1166	regulate	_	_	_	_
10-11	1167-1171	BMP2	object|abstract[63]	giv|new[63]	coref	20-10
10-12	1172-1180	activity	abstract[63]	new[63]	_	_
10-13	1181-1188	provide	_	_	_	_
10-14	1189-1197	powerful	abstract[64]	new[64]	_	_
10-15	1198-1203	tools	abstract[64]	new[64]	_	_
10-16	1204-1207	for	abstract[64]	new[64]	_	_
10-17	1208-1211	the	abstract[64]|event[65]	new[64]|new[65]	_	_
10-18	1212-1221	treatment	abstract[64]|event[65]	new[64]|new[65]	_	_
10-19	1222-1224	of	abstract[64]|event[65]	new[64]|new[65]	_	_
10-20	1225-1237	osteoporosis	abstract[64]|event[65]|object	new[64]|new[65]|giv	coref	13-35[82_0]
10-21	1238-1241	and	abstract[64]|event[65]	new[64]|new[65]	_	_
10-22	1242-1250	fracture	abstract[64]|event[65]|abstract|abstract[68]	new[64]|new[65]|new|new[68]	coref	14-8[0_68]
10-23	1251-1257	repair	abstract[64]|event[65]|abstract[68]	new[64]|new[65]|new[68]	_	_
10-24	1258-1259	.	_	_	_	_

#Text=Icariin ( ICA ) ( the chemical structure is shown in
11-1	1260-1267	Icariin	substance	new	_	_
11-2	1268-1269	(	_	_	_	_
11-3	1270-1273	ICA	abstract	new	coref	14-10
11-4	1274-1275	)	_	_	_	_
11-5	1276-1277	(	_	_	_	_
11-6	1278-1281	the	abstract[71]	new[71]	_	_
11-7	1282-1290	chemical	abstract[71]	new[71]	_	_
11-8	1291-1300	structure	abstract[71]	new[71]	_	_
11-9	1301-1303	is	_	_	_	_
11-10	1304-1309	shown	_	_	_	_
11-11	1310-1312	in	_	_	_	_

#Text=Figure 1
12-1	1313-1319	Figure	object[72]	new[72]	_	_
12-2	1320-1321	1	object[72]	new[72]	_	_

#Text=) is the main active flavonoid glucoside from herbs of the genus Epimedium ; these herbs are used in traditional Chinese medicine and have long been prescribed for the treatment of bone fractures and osteoporosis as a bone-protecting agent .
13-1	1322-1323	)	_	_	_	_
13-2	1324-1326	is	_	_	_	_
13-3	1327-1330	the	substance[73]	new[73]	_	_
13-4	1331-1335	main	substance[73]	new[73]	_	_
13-5	1336-1342	active	substance[73]	new[73]	_	_
13-6	1343-1352	flavonoid	substance[73]	new[73]	_	_
13-7	1353-1362	glucoside	substance[73]	new[73]	_	_
13-8	1363-1367	from	substance[73]	new[73]	_	_
13-9	1368-1373	herbs	substance[73]|plant[74]	new[73]|new[74]	coref	13-15[77_74]
13-10	1374-1376	of	substance[73]|plant[74]	new[73]|new[74]	_	_
13-11	1377-1380	the	substance[73]|plant[74]|place[76]	new[73]|new[74]|new[76]	_	_
13-12	1381-1386	genus	substance[73]|plant[74]|abstract|place[76]	new[73]|new[74]|new|new[76]	_	_
13-13	1387-1396	Epimedium	substance[73]|plant[74]|place[76]	new[73]|new[74]|new[76]	_	_
13-14	1397-1398	;	_	_	_	_
13-15	1399-1404	these	plant[77]	giv[77]	_	_
13-16	1405-1410	herbs	plant[77]	giv[77]	_	_
13-17	1411-1414	are	_	_	_	_
13-18	1415-1419	used	_	_	_	_
13-19	1420-1422	in	_	_	_	_
13-20	1423-1434	traditional	abstract[78]	new[78]	_	_
13-21	1435-1442	Chinese	abstract[78]	new[78]	_	_
13-22	1443-1451	medicine	abstract[78]	new[78]	_	_
13-23	1452-1455	and	_	_	_	_
13-24	1456-1460	have	_	_	_	_
13-25	1461-1465	long	_	_	_	_
13-26	1466-1470	been	_	_	_	_
13-27	1471-1481	prescribed	_	_	_	_
13-28	1482-1485	for	_	_	_	_
13-29	1486-1489	the	event[79]	new[79]	coref	15-9[99_79]
13-30	1490-1499	treatment	event[79]	new[79]	_	_
13-31	1500-1502	of	event[79]	new[79]	_	_
13-32	1503-1507	bone	event[79]|object|object[81]	new[79]|giv|giv[81]	coref	14-5
13-33	1508-1517	fractures	event[79]|object[81]	new[79]|giv[81]	_	_
13-34	1518-1521	and	event[79]|object[81]	new[79]|giv[81]	_	_
13-35	1522-1534	osteoporosis	event[79]|object[81]|object[82]	new[79]|giv[81]|giv[82]	coref	25-20[0_82]
13-36	1535-1537	as	event[79]|object[81]|object[82]	new[79]|giv[81]|giv[82]	_	_
13-37	1538-1539	a	event[79]|object[81]|object[82]	new[79]|giv[81]|giv[82]	_	_
13-38	1540-1555	bone-protecting	event[79]|object[81]|object[82]	new[79]|giv[81]|giv[82]	_	_
13-39	1556-1561	agent	event[79]|object[81]|object[82]	new[79]|giv[81]|giv[82]	_	_
13-40	1562-1563	.	_	_	_	_

#Text=In addition to promoting bone regeneration and repair , ICA also has many beneficial pharmacological and biological activities , including neuroprotective effects ; protective effects against atherosclerosis ; antitumor effects ; anti-inflammatory and antioxidant effects ; and improved sexual function effects .
14-1	1564-1566	In	_	_	_	_
14-2	1567-1575	addition	_	_	_	_
14-3	1576-1578	to	_	_	_	_
14-4	1579-1588	promoting	abstract[84]	new[84]	_	_
14-5	1589-1593	bone	object|abstract[84]	giv|new[84]	coref	15-18
14-6	1594-1606	regeneration	abstract[84]	new[84]	_	_
14-7	1607-1610	and	_	_	_	_
14-8	1611-1617	repair	abstract	giv	_	_
14-9	1618-1619	,	_	_	_	_
14-10	1620-1623	ICA	substance	giv	coref	15-11
14-11	1624-1628	also	_	_	_	_
14-12	1629-1632	has	_	_	_	_
14-13	1633-1637	many	abstract[87]	new[87]	appos	14-24[89_87]
14-14	1638-1648	beneficial	abstract[87]	new[87]	_	_
14-15	1649-1664	pharmacological	abstract[87]	new[87]	_	_
14-16	1665-1668	and	abstract[87]	new[87]	_	_
14-17	1669-1679	biological	abstract[87]	new[87]	_	_
14-18	1680-1690	activities	abstract[87]	new[87]	_	_
14-19	1691-1692	,	abstract[87]	new[87]	_	_
14-20	1693-1702	including	abstract[87]	new[87]	_	_
14-21	1703-1718	neuroprotective	abstract[87]|abstract[88]	new[87]|giv[88]	coref	14-29[92_88]
14-22	1719-1726	effects	abstract[87]|abstract[88]	new[87]|giv[88]	_	_
14-23	1727-1728	;	_	_	_	_
14-24	1729-1739	protective	abstract[89]	giv[89]	coref	24-19[165_89]
14-25	1740-1747	effects	abstract[89]	giv[89]	_	_
14-26	1748-1755	against	abstract[89]	giv[89]	_	_
14-27	1756-1771	atherosclerosis	abstract[89]|abstract	giv[89]|new	_	_
14-28	1772-1773	;	abstract[89]	giv[89]	_	_
14-29	1774-1783	antitumor	abstract[89]|abstract|abstract[92]	giv[89]|new|giv[92]	coref	14-32[93_92]
14-30	1784-1791	effects	abstract[89]|abstract[92]	giv[89]|giv[92]	_	_
14-31	1792-1793	;	abstract[89]	giv[89]	_	_
14-32	1794-1811	anti-inflammatory	abstract[89]|abstract[93]	giv[89]|giv[93]	coref	14-38[95_93]
14-33	1812-1815	and	abstract[89]|abstract[93]	giv[89]|giv[93]	_	_
14-34	1816-1827	antioxidant	abstract[89]|abstract[93]	giv[89]|giv[93]	_	_
14-35	1828-1835	effects	abstract[89]|abstract[93]	giv[89]|giv[93]	_	_
14-36	1836-1837	;	abstract[89]	giv[89]	_	_
14-37	1838-1841	and	abstract[89]	giv[89]	_	_
14-38	1842-1850	improved	abstract[89]|abstract[95]	giv[89]|giv[95]	coref	16-8[108_95]
14-39	1851-1857	sexual	abstract[89]|abstract[95]	giv[89]|giv[95]	_	_
14-40	1858-1866	function	abstract[89]|abstract|abstract[95]	giv[89]|new|giv[95]	_	_
14-41	1867-1874	effects	abstract[89]|abstract[95]	giv[89]|giv[95]	_	_
14-42	1875-1876	.	_	_	_	_

#Text=Several animal and cell studies have shown that treatment with ICA can increase osteogenic differentiation and reduce bone loss in vivo and in vitro .
15-1	1877-1884	Several	animal[96]	new[96]	_	_
15-2	1885-1891	animal	animal[96]	new[96]	_	_
15-3	1892-1895	and	_	_	_	_
15-4	1896-1900	cell	place|event[98]	new|new[98]	coref	18-1[117_98]
15-5	1901-1908	studies	event[98]	new[98]	_	_
15-6	1909-1913	have	_	_	_	_
15-7	1914-1919	shown	_	_	_	_
15-8	1920-1924	that	_	_	_	_
15-9	1925-1934	treatment	event[99]	giv[99]	ana	16-8[0_99]
15-10	1935-1939	with	event[99]	giv[99]	_	_
15-11	1940-1943	ICA	event[99]|substance	giv[99]|giv	coref	16-6
15-12	1944-1947	can	_	_	_	_
15-13	1948-1956	increase	_	_	_	_
15-14	1957-1967	osteogenic	event[101]	giv[101]	coref	17-10[115_101]
15-15	1968-1983	differentiation	event[101]	giv[101]	_	_
15-16	1984-1987	and	_	_	_	_
15-17	1988-1994	reduce	_	_	_	_
15-18	1995-1999	bone	object|abstract[103]	giv|new[103]	coref	16-10
15-19	2000-2004	loss	abstract[103]	new[103]	_	_
15-20	2005-2007	in	abstract[103]	new[103]	_	_
15-21	2008-2012	vivo	abstract[103]	new[103]	_	_
15-22	2013-2016	and	_	_	_	_
15-23	2017-2019	in	_	_	_	_
15-24	2020-2025	vitro	_	_	_	_
15-25	2026-2027	.	_	_	_	_

#Text=The extremely low cost of ICA and its strong bone regenerative effects indicate its potential in clinical applications .
16-1	2028-2031	The	abstract[104]	new[104]	_	_
16-2	2032-2041	extremely	abstract[104]	new[104]	_	_
16-3	2042-2045	low	abstract[104]	new[104]	_	_
16-4	2046-2050	cost	abstract[104]	new[104]	_	_
16-5	2051-2053	of	abstract[104]	new[104]	_	_
16-6	2054-2057	ICA	abstract[104]|substance	new[104]|giv	coref	20-8
16-7	2058-2061	and	_	_	_	_
16-8	2062-2065	its	event|abstract[108]	giv|giv[108]	ana	16-14
16-9	2066-2072	strong	abstract[108]	giv[108]	_	_
16-10	2073-2077	bone	object|abstract[108]	giv|giv[108]	coref	19-27
16-11	2078-2090	regenerative	abstract[108]	giv[108]	_	_
16-12	2091-2098	effects	abstract[108]	giv[108]	_	_
16-13	2099-2107	indicate	_	_	_	_
16-14	2108-2111	its	event|abstract[110]	giv|new[110]	_	_
16-15	2112-2121	potential	abstract[110]	new[110]	_	_
16-16	2122-2124	in	abstract[110]	new[110]	_	_
16-17	2125-2133	clinical	abstract[110]|abstract[111]	new[110]|new[111]	_	_
16-18	2134-2146	applications	abstract[110]|abstract[111]	new[110]|new[111]	_	_
16-19	2147-2148	.	_	_	_	_

#Text=The cAMP/PKA/CREB axis is a vital pathway that regulates osteogenic differentiation and mineralization .
17-1	2149-2152	The	abstract[113]	new[113]	coref	17-5[114_113]
17-2	2153-2166	cAMP/PKA/CREB	object|abstract[113]	new|new[113]	coref	18-14
17-3	2167-2171	axis	abstract[113]	new[113]	_	_
17-4	2172-2174	is	_	_	_	_
17-5	2175-2176	a	abstract[114]	giv[114]	coref	18-13[121_114]
17-6	2177-2182	vital	abstract[114]	giv[114]	_	_
17-7	2183-2190	pathway	abstract[114]	giv[114]	_	_
17-8	2191-2195	that	_	_	_	_
17-9	2196-2205	regulates	_	_	_	_
17-10	2206-2216	osteogenic	event[115]	giv[115]	coref	22-12[153_115]
17-11	2217-2232	differentiation	event[115]	giv[115]	_	_
17-12	2233-2236	and	_	_	_	_
17-13	2237-2251	mineralization	substance	new	_	_
17-14	2252-2253	.	_	_	_	_

#Text=Several previous studies have reported that PTH affects osteoblastic cells by activating the cAMP/PKA/CREB axis .
18-1	2254-2261	Several	event[117]	giv[117]	coref	19-1[122_117]
18-2	2262-2270	previous	event[117]	giv[117]	_	_
18-3	2271-2278	studies	event[117]	giv[117]	_	_
18-4	2279-2283	have	_	_	_	_
18-5	2284-2292	reported	_	_	_	_
18-6	2293-2297	that	_	_	_	_
18-7	2298-2301	PTH	abstract	new	_	_
18-8	2302-2309	affects	_	_	_	_
18-9	2310-2322	osteoblastic	object[119]	new[119]	coref	19-8[126_119]
18-10	2323-2328	cells	object[119]	new[119]	_	_
18-11	2329-2331	by	_	_	_	_
18-12	2332-2342	activating	_	_	_	_
18-13	2343-2346	the	abstract[121]	giv[121]	coref	23-11[160_121]
18-14	2347-2360	cAMP/PKA/CREB	object|abstract[121]	giv|giv[121]	coref	23-12
18-15	2361-2365	axis	abstract[121]	giv[121]	_	_
18-16	2366-2367	.	_	_	_	_

#Text=Several studies have reported that pretreatment of human mesenchymal stem cells ( MSCs ) with cAMP analogs , adenylate cyclase activators or phosphodiesterase inhibitors can enhance bone formation .
19-1	2368-2375	Several	event[122]	giv[122]	_	_
19-2	2376-2383	studies	event[122]	giv[122]	_	_
19-3	2384-2388	have	_	_	_	_
19-4	2389-2397	reported	_	_	_	_
19-5	2398-2402	that	_	_	_	_
19-6	2403-2415	pretreatment	abstract[123]	new[123]	_	_
19-7	2416-2418	of	abstract[123]	new[123]	_	_
19-8	2419-2424	human	abstract[123]|object[126]	new[123]|giv[126]	appos	19-13[0_126]
19-9	2425-2436	mesenchymal	abstract[123]|animal|object[126]	new[123]|new|giv[126]	_	_
19-10	2437-2441	stem	abstract[123]|plant|object[126]	new[123]|new|giv[126]	_	_
19-11	2442-2447	cells	abstract[123]|object[126]	new[123]|giv[126]	_	_
19-12	2448-2449	(	abstract[123]	new[123]	_	_
19-13	2450-2454	MSCs	abstract[123]|object	new[123]|giv	coref	21-15[147_0]
19-14	2455-2456	)	abstract[123]	new[123]	_	_
19-15	2457-2461	with	abstract[123]	new[123]	_	_
19-16	2462-2466	cAMP	abstract[123]|abstract|substance[129]	new[123]|new|new[129]	_	_
19-17	2467-2474	analogs	abstract[123]|substance[129]	new[123]|new[129]	_	_
19-18	2475-2476	,	abstract[123]	new[123]	_	_
19-19	2477-2486	adenylate	abstract[123]|substance|place[132]	new[123]|new|new[132]	_	_
19-20	2487-2494	cyclase	abstract[123]|abstract|place[132]	new[123]|new|new[132]	_	_
19-21	2495-2505	activators	abstract[123]|place[132]	new[123]|new[132]	_	_
19-22	2506-2508	or	abstract[123]	new[123]	_	_
19-23	2509-2526	phosphodiesterase	abstract[123]|object|substance[134]	new[123]|new|new[134]	_	_
19-24	2527-2537	inhibitors	abstract[123]|substance[134]	new[123]|new[134]	_	_
19-25	2538-2541	can	_	_	_	_
19-26	2542-2549	enhance	_	_	_	_
19-27	2550-2554	bone	object|event[136]	giv|giv[136]	coref	25-16
19-28	2555-2564	formation	event[136]	giv[136]	_	_
19-29	2565-2566	.	_	_	_	_

#Text=In the present study , we combined ICA and BMP2 to promote osteogenesis for the first time .
20-1	2567-2569	In	_	_	_	_
20-2	2570-2573	the	abstract[137]	new[137]	_	_
20-3	2574-2581	present	abstract[137]	new[137]	_	_
20-4	2582-2587	study	abstract[137]	new[137]	_	_
20-5	2588-2589	,	_	_	_	_
20-6	2590-2592	we	person	acc	ana	21-1
20-7	2593-2601	combined	abstract	new	coref|none	22-4[149_0]|20-7[0_167]
20-8	2602-2605	ICA	substance	giv	coref	21-6
20-9	2606-2609	and	_	_	_	_
20-10	2610-2614	BMP2	object	giv	coref	21-13
20-11	2615-2617	to	_	_	_	_
20-12	2618-2625	promote	_	_	_	_
20-13	2626-2638	osteogenesis	abstract	new	coref	23-7[157_0]
20-14	2639-2642	for	_	_	_	_
20-15	2643-2646	the	time[142]	new[142]	_	_
20-16	2647-2652	first	time[142]	new[142]	_	_
20-17	2653-2657	time	time[142]	new[142]	_	_
20-18	2658-2659	.	_	_	_	_

#Text=We aimed to determine whether ICA could enhance the osteogenic induction of BMP2 in C2C12 cells .
21-1	2660-2662	We	person	giv	ana	22-1
21-2	2663-2668	aimed	_	_	_	_
21-3	2669-2671	to	_	_	_	_
21-4	2672-2681	determine	_	_	_	_
21-5	2682-2689	whether	_	_	_	_
21-6	2690-2693	ICA	place	giv	coref	22-7
21-7	2694-2699	could	_	_	_	_
21-8	2700-2707	enhance	_	_	_	_
21-9	2708-2711	the	abstract[145]	new[145]	_	_
21-10	2712-2722	osteogenic	abstract[145]	new[145]	_	_
21-11	2723-2732	induction	abstract[145]	new[145]	_	_
21-12	2733-2735	of	abstract[145]	new[145]	_	_
21-13	2736-2740	BMP2	abstract[145]|abstract	new[145]|giv	coref	22-9
21-14	2741-2743	in	_	_	_	_
21-15	2744-2749	C2C12	object[147]	giv[147]	_	_
21-16	2750-2755	cells	object[147]	giv[147]	_	_
21-17	2756-2757	.	_	_	_	_

#Text=We concluded that the combination of ICA and BMP2 could promote BMP2-mediated osteoblast differentiation in a dose-dependent manner .
22-1	2758-2760	We	person	giv	ana	23-1
22-2	2761-2770	concluded	_	_	_	_
22-3	2771-2775	that	_	_	_	_
22-4	2776-2779	the	abstract[149]	new[149]	coref	25-1[167_149]
22-5	2780-2791	combination	abstract[149]	new[149]	_	_
22-6	2792-2794	of	abstract[149]	new[149]	_	_
22-7	2795-2798	ICA	abstract[149]|substance	new[149]|giv	coref	23-5
22-8	2799-2802	and	abstract[149]	new[149]	_	_
22-9	2803-2807	BMP2	abstract[149]|object	new[149]|giv	coref	24-12
22-10	2808-2813	could	_	_	_	_
22-11	2814-2821	promote	_	_	_	_
22-12	2822-2835	BMP2-mediated	event[153]	giv[153]	_	_
22-13	2836-2846	osteoblast	event|event[153]	giv|giv[153]	_	_
22-14	2847-2862	differentiation	event[153]	giv[153]	_	_
22-15	2863-2865	in	_	_	_	_
22-16	2866-2867	a	abstract[154]	new[154]	_	_
22-17	2868-2882	dose-dependent	abstract[154]	new[154]	_	_
22-18	2883-2889	manner	abstract[154]	new[154]	_	_
22-19	2890-2891	.	_	_	_	_

#Text=We also found that ICA stimulates BMP2-mediated osteogenesis by activating the cAMP/PKA/CREB signaling pathway .
23-1	2892-2894	We	person	giv	_	_
23-2	2895-2899	also	_	_	_	_
23-3	2900-2905	found	_	_	_	_
23-4	2906-2910	that	_	_	_	_
23-5	2911-2914	ICA	place	giv	coref	24-3
23-6	2915-2925	stimulates	_	_	_	_
23-7	2926-2939	BMP2-mediated	abstract[157]	giv[157]	_	_
23-8	2940-2952	osteogenesis	abstract[157]	giv[157]	_	_
23-9	2953-2955	by	_	_	_	_
23-10	2956-2966	activating	_	_	_	_
23-11	2967-2970	the	abstract[160]	giv[160]	_	_
23-12	2971-2984	cAMP/PKA/CREB	abstract|abstract[160]	giv|giv[160]	_	_
23-13	2985-2994	signaling	abstract|abstract[160]	new|giv[160]	_	_
23-14	2995-3002	pathway	abstract[160]	giv[160]	_	_
23-15	3003-3004	.	_	_	_	_

#Text=Therefore , ICA is a promising candidate as an alternative for BMP2 or as a promoter for enhancing the therapeutic effects of BMP2 .
24-1	3005-3014	Therefore	_	_	_	_
24-2	3015-3016	,	_	_	_	_
24-3	3017-3020	ICA	abstract	giv	_	_
24-4	3021-3023	is	_	_	_	_
24-5	3024-3025	a	person[162]	new[162]	_	_
24-6	3026-3035	promising	person[162]	new[162]	_	_
24-7	3036-3045	candidate	person[162]	new[162]	_	_
24-8	3046-3048	as	person[162]	new[162]	_	_
24-9	3049-3051	an	person[162]	new[162]	_	_
24-10	3052-3063	alternative	person[162]	new[162]	_	_
24-11	3064-3067	for	person[162]	new[162]	_	_
24-12	3068-3072	BMP2	person[162]|object	new[162]|giv	coref	24-23
24-13	3073-3075	or	_	_	_	_
24-14	3076-3078	as	_	_	_	_
24-15	3079-3080	a	person[164]	new[164]	_	_
24-16	3081-3089	promoter	person[164]	new[164]	_	_
24-17	3090-3093	for	_	_	_	_
24-18	3094-3103	enhancing	_	_	_	_
24-19	3104-3107	the	abstract[165]	giv[165]	coref	25-8[170_165]
24-20	3108-3119	therapeutic	abstract[165]	giv[165]	_	_
24-21	3120-3127	effects	abstract[165]	giv[165]	_	_
24-22	3128-3130	of	abstract[165]	giv[165]	_	_
24-23	3131-3135	BMP2	abstract[165]|object	giv[165]|giv	coref	25-11
24-24	3136-3137	.	_	_	_	_

#Text=This combination will reduce the risk of side effects from BMP2 in the treatment of bone diseases such as osteoporosis .
25-1	3138-3142	This	abstract[167]	giv[167]	_	_
25-2	3143-3154	combination	abstract[167]	giv[167]	_	_
25-3	3155-3159	will	_	_	_	_
25-4	3160-3166	reduce	_	_	_	_
25-5	3167-3170	the	abstract[168]	new[168]	_	_
25-6	3171-3175	risk	abstract[168]	new[168]	_	_
25-7	3176-3178	of	abstract[168]	new[168]	_	_
25-8	3179-3183	side	abstract[168]|abstract|abstract[170]	new[168]|giv|giv[170]	_	_
25-9	3184-3191	effects	abstract[168]|abstract[170]	new[168]|giv[170]	_	_
25-10	3192-3196	from	abstract[168]|abstract[170]	new[168]|giv[170]	_	_
25-11	3197-3201	BMP2	abstract[168]|abstract[170]|substance	new[168]|giv[170]|giv	_	_
25-12	3202-3204	in	_	_	_	_
25-13	3205-3208	the	abstract[172]	new[172]	_	_
25-14	3209-3218	treatment	abstract[172]	new[172]	_	_
25-15	3219-3221	of	abstract[172]	new[172]	_	_
25-16	3222-3226	bone	abstract[172]|object|abstract[174]	new[172]|giv|giv[174]	_	_
25-17	3227-3235	diseases	abstract[172]|abstract[174]	new[172]|giv[174]	_	_
25-18	3236-3240	such	abstract[172]|abstract[174]	new[172]|giv[174]	_	_
25-19	3241-3243	as	abstract[172]|abstract[174]	new[172]|giv[174]	_	_
25-20	3244-3256	osteoporosis	abstract[172]|abstract[174]|object	new[172]|giv[174]|giv	_	_
25-21	3257-3258	.	_	_	_	_
